NASDAQ:AFMD Affimed (AFMD) Stock Price, News & Analysis → AI finds its first serious application (From Wall Street Star) (Ad) Free AFMD Stock Alerts $4.88 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$4.56▼$4.9950-Day Range$0.61▼$6.9052-Week Range$2.23▼$11.10Volume71,146 shsAverage Volume95,861 shsMarket Capitalization$74.32 millionP/E RatioN/ADividend YieldN/APrice Target$45.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Affimed alerts: Email Address Affimed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside822.1% Upside$45.00 Price TargetShort InterestHealthy1.66% of Float Sold ShortDividend StrengthN/ASustainability-1.95Upright™ Environmental ScoreNews Sentiment0.30Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.53) to ($3.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.83 out of 5 starsMedical Sector219th out of 907 stocksPharmaceutical Preparations Industry89th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAffimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAffimed has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.66% of the float of Affimed has been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Affimed has recently increased by 11.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAffimed does not currently pay a dividend.Dividend GrowthAffimed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAffimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.Environmental SustainabilityThe Environmental Impact score for Affimed is -1.95. Previous Next 2.4 News and Social Media Coverage News SentimentAffimed has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Affimed this week, compared to 2 articles on an average week.Search Interest14 people have searched for AFMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Affimed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Affimed is held by insiders.Percentage Held by InstitutionsOnly 30.82% of the stock of Affimed is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Affimed are expected to grow in the coming year, from ($4.53) to ($3.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Affimed is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Affimed is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAffimed has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Affimed Stock (NASDAQ:AFMD)Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.Read More AFMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AFMD Stock News HeadlinesApril 24, 2024 | finanznachrichten.deAffimed N.V.: Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyApril 24, 2024 | globenewswire.comAffimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 23, 2024 | americanbankingnews.comAffimed (NASDAQ:AFMD) Stock Crosses Below 50-Day Moving Average of $5.54April 1, 2024 | markets.businessinsider.comPromising Clinical Trials and Strategic Financial Management Affirm Buy Rating for AffimedApril 1, 2024 | finance.yahoo.comAffimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | markets.businessinsider.comBuy Rating Affirmed on Affimed: Promising Clinical Outlook and Robust Financial PositionMarch 31, 2024 | gurufocus.comQ4 2023 Affimed NV Earnings Call TranscriptApril 25, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 28, 2024 | markets.businessinsider.comHere's what Wall Street expects from Affimed's earningsMarch 28, 2024 | investorplace.comAFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023March 28, 2024 | globenewswire.comAffimed Reports 2023 Financial Results and Operational ProgressMarch 27, 2024 | benzinga.comA Preview Of Affimed's EarningsMarch 21, 2024 | globenewswire.comAffimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024March 13, 2024 | seekingalpha.comJefferies starts Cue at buy, cites partnering potentialMarch 8, 2024 | msn.comWhy Is Affimed (AFMD) Stock Moving Today?March 8, 2024 | investorplace.comWhy Is Affimed (AFMD) Stock Moving Today?March 7, 2024 | msn.comVaxxinity gains after early-stage data for Parkinson’s disease drugMarch 6, 2024 | finanznachrichten.deAffimed N.V.: Affimed Announces 1-for-10 Reverse Stock SplitMarch 6, 2024 | msn.comAffimed falls on 1-for-10 reverse stock splitMarch 6, 2024 | investorplace.com7 of the Best Speculative Stocks You Can Snag for Less Than $1March 6, 2024 | globenewswire.comAffimed Announces 1-for-10 Reverse Stock SplitJanuary 9, 2024 | marketwatch.comAffimed CEO Adi Hoess Steps Down; Co to Cut Up to 50% of WorkforceJanuary 9, 2024 | finanznachrichten.deAffimed N.V.: Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerJanuary 8, 2024 | marketwatch.comAffimed N.V. to Expand Cohort in Study of AFM24 Following Promising DataJanuary 8, 2024 | finance.yahoo.comAffimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerJanuary 8, 2024 | finance.yahoo.comAffimed Announces Leadership Change and Organizational RestructuringSee More Headlines Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/25/2024Next Earnings (Estimated)5/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AFMD CUSIPN/A CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees219Year FoundedN/APrice Target and Rating Average Stock Price Target$45.00 High Stock Price Target$70.00 Low Stock Price Target$10.00 Potential Upside/Downside+822.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($8.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,660,000.00 Net Margins-1,280.27% Pretax Margin-1,280.19% Return on Equity-118.17% Return on Assets-81.35% Debt Debt-to-Equity Ratio0.11 Current Ratio3.25 Quick Ratio3.23 Sales & Book Value Annual Sales$8.95 million Price / Sales8.30 Cash FlowN/A Price / Cash FlowN/A Book Value$4.19 per share Price / Book1.16Miscellaneous Outstanding Shares15,230,000Free Float14,648,000Market Cap$74.32 million OptionableOptionable Beta2.05 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Andreas Harstrick M.D. (Age 63)Interim CEO, Chief Medical Officer & Member of Management Board Comp: $535.09kDr. Wolfgang Fischer (Age 60)MD, COO & Member of Management Board Comp: $645.58kMs. Denise Mueller (Age 54)Chief Business Officer & Member of Management Board Comp: $628.24kProf. Melvyn LittleFounder & ConsultantMr. Michael Wolf (Age 57)Head of Finance & Administration Mr. Alexander FudukidisHead of Investor Relations & Director of Investor RelationsMary Beth SandinVice President of Marketing & CommunicationsMore ExecutivesKey CompetitorsLeap TherapeuticsNASDAQ:LPTXAileron TherapeuticsNASDAQ:ALRNLifeVantageNASDAQ:LFVNChimerixNASDAQ:CMRXInflaRxNASDAQ:IFRXView All CompetitorsInstitutional OwnershipHarbor Investment Advisory LLCSold 52,830 shares on 4/12/2024Ownership: 0.039%Vestal Point Capital LPBought 546,067 shares on 2/14/2024Ownership: 0.366%BNP Paribas Financial MarketsBought 163,162 shares on 2/7/2024Ownership: 0.383%EWA LLCBought 142,525 shares on 2/5/2024Ownership: 0.095%Simplex Trading LLCSold 100 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions AFMD Stock Analysis - Frequently Asked Questions Should I buy or sell Affimed stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AFMD shares. View AFMD analyst ratings or view top-rated stocks. What is Affimed's stock price target for 2024? 5 brokerages have issued twelve-month target prices for Affimed's shares. Their AFMD share price targets range from $10.00 to $70.00. On average, they predict the company's share price to reach $45.00 in the next year. This suggests a possible upside of 822.1% from the stock's current price. View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts. How have AFMD shares performed in 2024? Affimed's stock was trading at $6.25 at the beginning of 2024. Since then, AFMD shares have decreased by 21.9% and is now trading at $4.88. View the best growth stocks for 2024 here. Are investors shorting Affimed? Affimed saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 219,400 shares, an increase of 11.7% from the March 31st total of 196,400 shares. Based on an average daily trading volume, of 91,100 shares, the days-to-cover ratio is presently 2.4 days. Currently, 1.7% of the company's shares are short sold. View Affimed's Short Interest. When is Affimed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024. View our AFMD earnings forecast. How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by $0.10. The biopharmaceutical company had revenue of $10.21 million for the quarter, compared to analyst estimates of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 118.17% and a negative net margin of 1,280.27%. During the same period in the prior year, the business posted ($0.80) earnings per share. When did Affimed's stock split? Shares of Affimed reverse split on the morning of Monday, March 11th 2024. The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN). Who are Affimed's major shareholders? Affimed's stock is owned by many different institutional and retail investors. Top institutional shareholders include Harbor Investment Advisory LLC (0.04%). How do I buy shares of Affimed? Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AFMD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
